China Daily Briefing

WuXi AppTec's 9-month profit surge (+62.4% YoY, revenue +38.6%) with a raised full-year guidance is the clearest China earnings beat today. The CRDMO model thrives on global pharma R&D outsourcing, and this print confirms the US biotech spending cycle is alive irrespective of Sino-US tensions. SCMP Business noted the company's net profit through Q3 is substantial — the raised guidance implies management sees Q4 pipeline activity remaining strong. Key risk: US Treasury's proposed outbound investment restriction rules (separate SCMP story) could complicate deal structures.

SCMP Business reported that US Treasury's draft outbound investment restriction rules could complicate deal structures for Chinese biotech firms doing global licensing, even though drug licensing itself remains untouched. For WuXi AppTec specifically: the core pharma services business (CRDMO manufacturing, CRO research) appears insulated, but equity investment flows from US biotech into Chinese partners may slow. This is the headline risk that kept WuXi's sector peers more cautious even as WuXi itself raised guidance.

Local tax bureaus in Beijing and other cities are issuing disclosure orders for offshore trusts following the expiry of China's offshore reporting grace period, SCMP Business reported. Municipal authorities named 21 individuals in Beijing alone. For investors: this is a negative wealth-transfer signal for Chinese HNW investors with offshore structures — forced repatriation or disclosure could affect offshore demand for Hong Kong property and financial products. Watch ADR valuations of Chinese internet companies that hold significant cash offshore.